Yon K Sung, MD
Pulmonary Disease · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: El Camino Health · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Sung’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A99234 · Current
Licensed to practise in California · since 2007 · expires 2027-03-31 · University of Pittsburgh School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$56,722
Medicare paid this office $56,722 for 311 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 41 | $12,047 | $105 |
| Long return visit (40+ min) | 49 | $8,649 | $125 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 37 | $4,150 | $70 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 35 | $4,074 | $116 |
| Insertion of tube in right heart chambers for measurement | 32 | $3,310 | $103 |
See all 15 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 41 | $12,047 | $105 |
| Long return visit (40+ min) | 49 | $8,649 | $125 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 37 | $4,150 | $70 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 35 | $4,074 | $116 |
| Insertion of tube in right heart chambers for measurement | 32 | $3,310 | $103 |
| Return visit (30+ min) | 27 | $2,900 | $83 |
| Long return visit (40+ min) | 15 | $2,767 | $173 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $2,574 | $151 |
| Drug infusion during cardiac catheterization | 19 | $1,550 | $82 |
| Hospital discharge day management, 30 minutes or less | 11 | $1,039 | $74 |
| Test to examine how well the lungs exchange gases | 86 | $661 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 59 | $540 | $9 |
| Test to measure expiratory airflow and volume | 67 | $479 | $7 |
| Test to determine lung volumes using sensors | 40 | $417 | $10 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 35 | $368 | $11 |
Who their Medicare patients are
311 Original Medicare patients in 2024. Average age 72 · Under 65 16% · 85 and older 11% · Women 56% · Also on Medicaid 30% · Health risk score 2.40. Above the middle of the specialty; the typical pulmonary disease clinician is at 2.13.
Conditions among them: High blood pressure 75% · COPD 47% · Heart failure 45% · Coronary heart disease 42% · Chronic kidney disease 40% · Atrial fibrillation 34% · Diabetes 29% · Depression 24% · Cancer 22% · Stroke 12% · Dementia 11%.
The office billed $339,624, Medicare allowed $72,766 and paid $56,722; for 781 services of 31 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 311 | 781 | 72 | 2.40 | $339,624 | $56,722 |
| 2023 | 253 | 560 | 70 | 2.72 | $194,576 | $35,716 |
| 2022 | 324 | 773 | 72 | 2.19 | $253,713 | $51,404 |
| 2021 | 369 | 896 | 70 | 2.34 | $312,276 | $64,914 |
| 2020 | 386 | 879 | 71 | 2.29 | $238,039 | $52,146 |
| 2019 | 464 | 1,055 | 71 | 2.43 | $229,825 | $65,867 |
| 2018 | 388 | 856 | 70 | 2.41 | $168,380 | $55,193 |
| 2017 | 424 | 1,022 | 70 | 2.27 | $243,962 | $66,371 |
| 2016 | 447 | 1,049 | 70 | 2.09 | $233,727 | $60,493 |
| 2015 | 348 | 816 | 71 | 2.31 | $224,254 | $53,592 |
| 2014 | 241 | 514 | 70 | 1.95 | $130,872 | $37,505 |
| 2013 | 121 | 207 | 69 | 2.56 | $77,126 | $21,815 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 14 services
| Long return visit (40+ min) | 38 | $6,991 | $125 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 28 | $5,253 | $72 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 25 | $4,158 | $160 |
| Return visit (30+ min) | 34 | $3,274 | $84 |
| Insertion of tube in right heart chambers for measurement | 23 | $2,529 | $105 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $2,304 | $110 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,674 | $120 |
| Drug infusion during cardiac catheterization | 13 | $1,150 | $88 |
| Hospital discharge day management, 30 minutes or less | 11 | $835 | $70 |
| Test to examine how well the lungs exchange gases | 74 | $582 | $8 |
| Test to measure expiratory airflow and volume | 63 | $456 | $7 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 42 | $365 | $9 |
| Test to determine lung volumes using sensors | 29 | $299 | $10 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 20 | $95 | $5 |
2022: 14 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 34 | $8,710 | $94 |
| Long return visit (40+ min) | 38 | $7,119 | $127 |
| Return visit (30+ min) | 59 | $6,541 | $83 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $4,150 | $180 |
| Insertion of tube in right heart chambers for measurement | 30 | $3,571 | $115 |
| New patient visit (60+ min) | 16 | $2,783 | $174 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 19 | $2,325 | $122 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,948 | $65 |
| Drug infusion during cardiac catheterization | 17 | $1,530 | $90 |
| Test to examine how well the lungs exchange gases | 102 | $831 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 80 | $726 | $9 |
| Test to measure expiratory airflow and volume | 71 | $528 | $7 |
| Test to determine lung volumes using sensors | 47 | $506 | $11 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 31 | $153 | $5 |
2021: 16 services
| Return visit (30+ min) | 87 | $13,698 | $99 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 35 | $9,412 | $93 |
| Long return visit (40+ min) | 35 | $8,328 | $149 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $5,505 | $190 |
| Insertion of tube in right heart chambers for measurement | 33 | $3,732 | $113 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 30 | $3,360 | $65 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 21 | $2,631 | $125 |
| New patient visit (45+ min) | 15 | $2,117 | $141 |
| Drug infusion during cardiac catheterization | 18 | $1,636 | $91 |
| Hospital discharge day management, 30 minutes or less | 19 | $1,528 | $69 |
| Test to examine how well the lungs exchange gases | 108 | $906 | $8 |
| Test to measure expiratory airflow and volume | 91 | $725 | $8 |
| Short return visit (20+ min) | 11 | $695 | $58 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 48 | $454 | $9 |
| Test to determine lung volumes using sensors | 39 | $429 | $11 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 27 | $310 | $11 |
2020: 16 services
| Return visit (30+ min) | 117 | $13,460 | $70 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $7,509 | $98 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $5,083 | $188 |
| New patient visit (60+ min) | 31 | $4,393 | $142 |
| Insertion of tube in right heart chambers for measurement | 35 | $3,826 | $109 |
| Long return visit (40+ min) | 28 | $3,187 | $103 |
| Drug infusion during cardiac catheterization | 23 | $2,088 | $91 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $1,957 | $67 |
| Telephone medical discussion with physician, 21-30 minutes | 12 | $918 | $76 |
| Test to examine how well the lungs exchange gases | 110 | $887 | $8 |
| Test to measure expiratory airflow and volume | 95 | $709 | $7 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 60 | $663 | $11 |
| Short return visit (20+ min) | 11 | $526 | $48 |
| Test to determine lung volumes using sensors | 48 | $510 | $11 |
| Telephone medical discussion with physician, 11-20 minutes | 12 | $438 | $36 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 29 | $318 | $11 |
2019: 13 services
| Return visit (30+ min) | 144 | $15,817 | $69 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 36 | $6,975 | $184 |
| New patient visit (60+ min) | 47 | $6,968 | $148 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 30 | $6,320 | $94 |
| Long return visit (40+ min) | 48 | $5,900 | $98 |
| Insertion of tube in right heart chambers for measurement | 46 | $4,780 | $102 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 29 | $3,961 | $66 |
| Drug infusion during cardiac catheterization | 25 | $2,261 | $87 |
| Test to examine how well the lungs exchange gases | 132 | $1,125 | $8 |
| Test to measure expiratory airflow and volume | 120 | $948 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 63 | $768 | $12 |
| Test to determine lung volumes using sensors | 45 | $519 | $11 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 39 | $426 | $11 |
2018: 14 services
| Return visit (30+ min) | 150 | $17,830 | $66 |
| New patient visit (60+ min) | 50 | $7,106 | $142 |
| Long return visit (40+ min) | 54 | $5,852 | $98 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 32 | $5,612 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 25 | $4,730 | $182 |
| Insertion of tube in right heart chambers for measurement | 30 | $3,274 | $109 |
| Drug infusion during cardiac catheterization | 16 | $1,417 | $89 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $1,046 | $65 |
| Test to examine how well the lungs exchange gases | 80 | $657 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 47 | $531 | $11 |
| Test to determine lung volumes using sensors | 33 | $356 | $11 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 31 | $342 | $11 |
| Test to measure expiratory airflow and volume | 44 | $342 | $8 |
| Test to measure expiratory airflow and volume | 28 | $213 | $8 |
2017: 15 services
| Return visit (30+ min) | 162 | $17,581 | $67 |
| New patient visit (60+ min) | 57 | $8,138 | $143 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $8,039 | $93 |
| Long return visit (40+ min) | 50 | $5,416 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $5,076 | $181 |
| Insertion of tube in right heart chambers for measurement | 40 | $4,490 | $110 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 23 | $3,369 | $65 |
| Drug infusion during cardiac catheterization | 21 | $1,896 | $86 |
| Short return visit (20+ min) | 22 | $1,324 | $44 |
| Test to examine how well the lungs exchange gases | 102 | $845 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 43 | $507 | $12 |
| Test to measure expiratory airflow and volume | 65 | $501 | $8 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 40 | $436 | $11 |
| Test to determine lung volumes using sensors | 39 | $433 | $11 |
| Test to measure expiratory airflow and volume | 25 | $190 | $7 |
2016: 16 services
| Return visit (30+ min) | 116 | $12,175 | $68 |
| New patient visit (60+ min) | 54 | $8,085 | $150 |
| Long return visit (40+ min) | 49 | $5,678 | $98 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 37 | $5,530 | $64 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $4,867 | $180 |
| Insertion of tube in right heart chambers for measurement | 34 | $4,227 | $124 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 24 | $4,074 | $93 |
| Drug infusion during cardiac catheterization | 20 | $1,766 | $88 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,458 | $121 |
| Short return visit (20+ min) | 25 | $1,223 | $39 |
| Test to examine how well the lungs exchange gases | 152 | $1,204 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 88 | $989 | $11 |
| Hospital discharge day management, 30 minutes or less | 12 | $920 | $66 |
| Test to determine lung volumes using sensors | 69 | $716 | $10 |
| Test to measure expiratory airflow and volume | 88 | $638 | $7 |
| Test to measure expiratory airflow and volume | 25 | $190 | $7 |
2015: 15 services
| Return visit (30+ min) | 98 | $10,560 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 47 | $6,552 | $64 |
| Critical care, first 30-74 minutes | 11 | $6,001 | $194 |
| New patient visit (45+ min) | 46 | $5,081 | $110 |
| Long return visit (40+ min) | 38 | $4,966 | $99 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 28 | $3,535 | $122 |
| New patient visit (60+ min) | 23 | $3,395 | $148 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $3,075 | $181 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $3,000 | $91 |
| Short return visit (20+ min) | 21 | $1,174 | $43 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 12 | $1,083 | $90 |
| Test to examine how well the lungs exchange gases | 90 | $742 | $8 |
| Test to measure expiratory airflow and volume | 71 | $531 | $7 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 45 | $515 | $11 |
| Test to determine lung volumes using sensors | 27 | $293 | $11 |
2014: 14 services
| Return visit (30+ min) | 62 | $6,750 | $68 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 43 | $6,405 | $64 |
| Critical care, first 30-74 minutes | 28 | $5,968 | $186 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 24 | $2,921 | $122 |
| New patient visit (60+ min) | 18 | $2,692 | $150 |
| New patient visit (45+ min) | 22 | $2,543 | $116 |
| Long return visit (40+ min) | 22 | $2,467 | $95 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $1,103 | $92 |
| Hospital discharge day management, 30 minutes or less | 16 | $1,048 | $65 |
| Short return visit (20+ min) | 13 | $591 | $45 |
| Test to examine how well the lungs exchange gases | 39 | $310 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 20 | $223 | $11 |
| Test to measure expiratory airflow and volume | 29 | $220 | $8 |
| Test to determine lung volumes using sensors | 11 | $111 | $10 |
2013: 3 services
| Critical care, first 30-74 minutes | 38 | $9,661 | $186 |
| Return visit (30+ min) | 54 | $5,520 | $67 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $1,612 | $62 |
Medicaid work
$2,389 in 2023
Medicaid paid $2,389 for 94 billed services this clinician did in 2023, up to 19 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 45 | $2,096 |
| Diffusing capacity | 32 | $196 |
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 17 | $97 |
| 2023 | 94 | 3 | 19 | $2,389 |
| 2022 | 37 | 2 | 13 | $172 |
| 2021 | 47 | 3 | 19 | $489 |
| 2020 | 67 | 2 | 14 | $1,583 |
| 2019 | 134 | 4 | 25 | $3,439 |
| 2018 | 67 | 3 | 15 | $1,254 |
See the largest Medicaid services in earlier years
2022
| Diffusing capacity | 25 | $112 |
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 12 | $60 |
2021
| Return visit (30+ min) | 13 | $320 |
| Diffusing capacity | 19 | $93 |
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 15 | $76 |
2020
| Return visit (30+ min) | 53 | $1,551 |
| Diffusing capacity | 14 | $33 |
2019
| Return visit (30+ min) | 78 | $2,732 |
| EVALUATION OF WHEEZING | 19 | $429 |
| Diffusing capacity | 25 | $202 |
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 12 | $76 |
2018
| Return visit (30+ min) | 40 | $1,052 |
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 13 | $104 |
| Diffusing capacity | 14 | $99 |
Drugs they prescribed that Part D paid
$4,540,124
Pharmacies billed $4,540,124 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
511 generic and 554 brand-name prescriptions · $4,540,124 in drug cost · 16 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Adempas | 97 | $1,311,239 | $13,518 |
| Uptravi | 50 | $1,125,010 | $22,500 |
| Opsumit | 85 | $1,055,076 | $12,413 |
| Tyvaso Dpi | 14 | $280,478 | $20,034 |
| Winrevair | 19 | $239,089 | $12,584 |
See all 26 drugs
| Adempas | 97 | $1,311,239 | $13,518 |
| Uptravi | 50 | $1,125,010 | $22,500 |
| Opsumit | 85 | $1,055,076 | $12,413 |
| Tyvaso Dpi | 14 | $280,478 | $20,034 |
| Winrevair | 19 | $239,089 | $12,584 |
| Ambrisentan | 70 | $182,585 | $2,608 |
| Trelegy Ellipta | 78 | $59,787 | $767 |
| Tadalafil | 44 | $50,828 | $1,155 |
| Spiriva Respimat | 39 | $26,274 | $674 |
| Eliquis | 22 | $20,630 | $938 |
| Sildenafil Citrate | 85 | $15,486 | $182 |
| Xarelto | 17 | $9,408 | $553 |
| Atrovent Hfa | 15 | $6,806 | $454 |
| Breo Ellipta | 13 | $6,601 | $508 |
| Symbicort | 11 | $4,608 | $419 |
| Breyna | 16 | $3,485 | $218 |
| Budesonide-Formoterol | 11 | $1,329 | $121 |
| Albuterol Sulfate Hfa | 26 | $1,068 | $41 |
| Ipratropium | 15 | $484 | $32 |
| Fluticasone Propionate | 27 | $348 | $13 |
| Montelukast | 34 | $299 | $9 |
| Potassium Chloride | 12 | $250 | $21 |
| Pantoprazole | 11 | $232 | $21 |
| Prednisone | 18 | $153 | $8 |
| Spironolactone | 12 | $120 | $10 |
| Furosemide | 56 | $106 | $2 |
Year by year
| 2024 | 1,065 | 95 | None | 52% | $4,540,124 |
| 2023 | 850 | 92 | None | 51% | $3,219,234 |
| 2022 | 917 | 92 | None | 52% | $2,361,043 |
| 2021 | 899 | 85 | 1% (11) | 56% | $2,864,118 |
| 2020 | 950 | 101 | None | 56% | $2,621,921 |
| 2019 | 981 | 132 | None | 60% | $2,187,442 |
| 2018 | 1,073 | 133 | None | 67% | $2,017,212 |
| 2017 | 969 | 156 | None | 64% | $1,892,246 |
| 2016 | 695 | 113 | None | 70% | $1,484,965 |
| 2015 | 488 | 91 | None | 66% | $1,034,415 |
| 2014 | 328 | 64 | None | 55% | $638,489 |
| 2013 | 217 | 33 | None | 68% | $547,695 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 22 drugs
| Adempas | 55 | $758,797 | $13,796 |
| Opsumit | 58 | $714,018 | $12,311 |
| Uptravi | 34 | $677,259 | $19,919 |
| Ambrisentan | 61 | $392,175 | $6,429 |
| Tyvaso Dpi | 12 | $272,494 | $22,708 |
| Bosentan | 12 | $129,199 | $10,767 |
| Tadalafil | 44 | $56,579 | $1,286 |
| Trelegy Ellipta | 50 | $43,338 | $867 |
| Sildenafil Citrate | 84 | $39,930 | $475 |
| Spiriva Respimat | 44 | $28,049 | $637 |
| Breo Ellipta | 22 | $10,171 | $462 |
| Symbicort | 16 | $8,968 | $561 |
| Advair Hfa | 14 | $6,220 | $444 |
| Flovent Hfa | 13 | $6,035 | $464 |
| Ventolin Hfa | 23 | $1,429 | $62 |
| Albuterol Sulfate Hfa | 29 | $1,369 | $47 |
| Fluticasone Propionate | 27 | $660 | $24 |
| Montelukast | 24 | $641 | $27 |
| Ipratropium | 15 | $383 | $26 |
| Azithromycin | 11 | $228 | $21 |
| Furosemide | 27 | $199 | $7 |
| Prednisone | 16 | $132 | $8 |
2022: 24 drugs
| Adempas | 53 | $680,458 | $12,839 |
| Opsumit | 52 | $596,141 | $11,464 |
| Uptravi | 19 | $381,168 | $20,061 |
| Ambrisentan | 68 | $318,242 | $4,680 |
| Tadalafil | 50 | $93,326 | $1,867 |
| Sildenafil Citrate | 80 | $38,382 | $480 |
| Trelegy Ellipta | 41 | $35,043 | $855 |
| Symbicort | 43 | $22,760 | $529 |
| Spiriva Respimat | 28 | $19,706 | $704 |
| Flovent Hfa | 36 | $15,828 | $440 |
| Atrovent Hfa | 24 | $15,314 | $638 |
| Breo Ellipta | 27 | $12,531 | $464 |
| Anoro Ellipta | 14 | $7,438 | $531 |
| Stiolto Respimat | 12 | $5,859 | $488 |
| Budesonide-Formoterol | 11 | $5,115 | $465 |
| Albuterol Sulfate Hfa | 51 | $2,259 | $44 |
| Azelastine-Fluticasone | 11 | $1,728 | $157 |
| Azelastine | 18 | $1,121 | $62 |
| Montelukast | 38 | $764 | $20 |
| Fluticasone Propionate | 17 | $400 | $24 |
| Azithromycin | 18 | $233 | $13 |
| Prednisone | 13 | $91 | $7 |
| Furosemide | 25 | $91 | $4 |
| Spironolactone | 14 | $81 | $6 |
2021: 21 drugs
| Uptravi | 47 | $837,176 | $17,812 |
| Adempas | 53 | $675,944 | $12,754 |
| Opsumit | 62 | $660,485 | $10,653 |
| Ambrisentan | 67 | $262,173 | $3,913 |
| Tadalafil | 43 | $76,418 | $1,777 |
| Adcirca | 15 | $71,919 | $4,795 |
| Bosentan | 20 | $40,503 | $2,025 |
| Symbicort | 58 | $34,474 | $594 |
| Spiriva Respimat | 48 | $30,967 | $645 |
| Sildenafil Citrate | 63 | $26,263 | $417 |
| Flovent Hfa | 42 | $18,144 | $432 |
| Advair Diskus | 19 | $9,327 | $491 |
| Breo Ellipta | 21 | $8,193 | $390 |
| Advair Hfa | 11 | $6,162 | $560 |
| Azelastine-Fluticasone | 15 | $2,059 | $137 |
| Albuterol Sulfate Hfa | 29 | $1,228 | $42 |
| Fluticasone Propionate | 19 | $360 | $19 |
| Spironolactone | 11 | $321 | $29 |
| Montelukast | 29 | $305 | $11 |
| Azithromycin | 19 | $284 | $15 |
| Furosemide | 32 | $215 | $7 |
2020: 25 drugs
| Adempas | 55 | $724,198 | $13,167 |
| Opsumit | 45 | $460,549 | $10,234 |
| Uptravi | 21 | $384,806 | $18,324 |
| Ambrisentan | 63 | $373,605 | $5,930 |
| Letairis | 18 | $180,297 | $10,017 |
| Adcirca | 16 | $67,982 | $4,249 |
| Spiriva Respimat | 64 | $36,183 | $565 |
| Symbicort | 63 | $34,997 | $556 |
| Alyq | 32 | $33,982 | $1,062 |
| Bosentan | 11 | $32,127 | $2,921 |
| Tadalafil | 26 | $30,671 | $1,180 |
| Flovent Hfa | 34 | $15,322 | $451 |
| Eliquis | 21 | $10,199 | $486 |
| Advair Diskus | 13 | $6,063 | $466 |
| Sildenafil Citrate | 82 | $5,514 | $67 |
| Wixela Inhub | 17 | $5,066 | $298 |
| Advair Hfa | 11 | $3,604 | $328 |
| Albuterol Sulfate Hfa | 40 | $2,108 | $53 |
| Proair Hfa | 18 | $1,354 | $75 |
| Ventolin Hfa | 12 | $700 | $58 |
| Montelukast | 40 | $532 | $13 |
| Azithromycin | 22 | $512 | $23 |
| Fluticasone Propionate | 15 | $373 | $25 |
| Furosemide | 36 | $287 | $8 |
| Prednisone | 15 | $85 | $6 |
2019: 27 drugs
| Adempas | 61 | $618,790 | $10,144 |
| Opsumit | 36 | $351,716 | $9,770 |
| Letairis | 35 | $348,044 | $9,944 |
| Uptravi | 14 | $221,311 | $15,808 |
| Ambrisentan | 18 | $137,652 | $7,647 |
| Tadalafil | 20 | $43,303 | $2,165 |
| Orenitram Er | 19 | $40,293 | $2,121 |
| Symbicort | 66 | $35,139 | $532 |
| Spiriva Respimat | 54 | $29,015 | $537 |
| Flovent Hfa | 70 | $27,615 | $394 |
| Alyq | 19 | $24,388 | $1,284 |
| Spiriva | 29 | $23,136 | $798 |
| Sildenafil Citrate | 87 | $18,418 | $212 |
| Advair Diskus | 18 | $11,801 | $656 |
| Incruse Ellipta | 11 | $5,738 | $522 |
| Eliquis | 11 | $4,843 | $440 |
| Advair Hfa | 11 | $3,782 | $344 |
| Wixela Inhub | 13 | $2,466 | $190 |
| Ventolin Hfa | 33 | $2,072 | $63 |
| Proair Hfa | 20 | $1,720 | $86 |
| Azithromycin | 33 | $1,300 | $39 |
| Spironolactone | 14 | $398 | $28 |
| Montelukast | 34 | $377 | $11 |
| Fluticasone Propionate | 26 | $358 | $14 |
| Furosemide | 28 | $326 | $12 |
| Potassium Chloride | 12 | $265 | $22 |
| Prednisone | 20 | $141 | $7 |
2018: 21 drugs
| Letairis | 56 | $542,832 | $9,693 |
| Adempas | 49 | $484,789 | $9,894 |
| Opsumit | 33 | $300,608 | $9,109 |
| Adcirca | 63 | $260,561 | $4,136 |
| Symbicort | 91 | $33,034 | $363 |
| Spiriva Respimat | 70 | $32,879 | $470 |
| Sildenafil | 101 | $32,419 | $321 |
| Spiriva | 45 | $23,635 | $525 |
| Advair Diskus | 42 | $21,280 | $507 |
| Flovent Hfa | 43 | $15,503 | $361 |
| Incruse Ellipta | 22 | $8,563 | $389 |
| Xarelto | 12 | $5,325 | $444 |
| Ventolin Hfa | 45 | $2,471 | $55 |
| Proair Hfa | 36 | $2,324 | $65 |
| Potassium Chloride | 19 | $2,252 | $119 |
| Azithromycin | 30 | $1,200 | $40 |
| Montelukast | 38 | $481 | $13 |
| Fluticasone Propionate | 31 | $416 | $13 |
| Furosemide | 67 | $350 | $5 |
| Loperamide | 11 | $154 | $14 |
| Prednisone | 18 | $116 | $6 |
2017: 25 drugs
| Letairis | 41 | $387,168 | $9,443 |
| Adcirca | 95 | $346,211 | $3,644 |
| Opsumit | 33 | $276,560 | $8,381 |
| Uptravi | 13 | $232,206 | $17,862 |
| Orenitram Er | 35 | $196,513 | $5,615 |
| Adempas | 19 | $180,960 | $9,524 |
| Sildenafil | 68 | $35,338 | $520 |
| Symbicort | 82 | $26,389 | $322 |
| Spiriva | 23 | $14,082 | $612 |
| Spiriva Respimat | 38 | $13,996 | $368 |
| Flovent Hfa | 28 | $10,181 | $364 |
| Advair Diskus | 25 | $9,860 | $394 |
| Advair Hfa | 13 | $6,291 | $484 |
| Incruse Ellipta | 13 | $4,272 | $329 |
| Proair Hfa | 22 | $1,362 | $62 |
| Ventolin Hfa | 23 | $1,230 | $53 |
| Bumetanide | 17 | $997 | $59 |
| Montelukast | 19 | $879 | $46 |
| Azithromycin | 23 | $867 | $38 |
| Potassium Chloride | 14 | $557 | $40 |
| Spironolactone | 31 | $356 | $11 |
| Furosemide | 68 | $324 | $5 |
| Prednisone | 26 | $228 | $9 |
| Fluticasone Propionate | 18 | $193 | $11 |
| Loperamide | 12 | $146 | $12 |
2016: 20 drugs
| Tracleer | 36 | $342,834 | $9,523 |
| Letairis | 37 | $319,717 | $8,641 |
| Opsumit | 35 | $267,304 | $7,637 |
| Adcirca | 68 | $202,769 | $2,982 |
| Orenitram Er | 32 | $103,510 | $3,235 |
| Sildenafil | 48 | $25,888 | $539 |
| Advair Diskus | 51 | $24,225 | $475 |
| Spiriva | 49 | $18,499 | $378 |
| Symbicort | 28 | $10,136 | $362 |
| Spiriva Respimat | 16 | $5,373 | $336 |
| Flovent Hfa | 16 | $4,071 | $254 |
| Proair Hfa | 32 | $1,876 | $59 |
| Asmanex | 11 | $1,856 | $169 |
| Ventolin Hfa | 22 | $1,244 | $57 |
| Bumetanide | 11 | $449 | $41 |
| Montelukast | 15 | $304 | $20 |
| Pantoprazole | 11 | $198 | $18 |
| Fluticasone Propionate | 16 | $196 | $12 |
| Furosemide | 33 | $190 | $6 |
| Prednisone | 12 | $102 | $8 |
2015: 12 drugs
| Opsumit | 40 | $290,610 | $7,265 |
| Letairis | 37 | $280,082 | $7,570 |
| Tracleer | 25 | $214,917 | $8,597 |
| Adcirca | 57 | $141,467 | $2,482 |
| Advair Diskus | 28 | $16,470 | $588 |
| Sildenafil | 44 | $11,098 | $252 |
| Spiriva | 23 | $9,265 | $403 |
| Symbicort | 11 | $3,267 | $297 |
| Proair Hfa | 30 | $1,740 | $58 |
| Spironolactone | 19 | $318 | $17 |
| Furosemide | 30 | $156 | $5 |
| Montelukast | 16 | $147 | $9 |
2014: 6 drugs
| Letairis | 41 | $291,188 | $7,102 |
| Tracleer | 22 | $167,643 | $7,620 |
| Adcirca | 34 | $57,143 | $1,681 |
| Sildenafil | 23 | $10,215 | $444 |
| Spironolactone | 31 | $464 | $15 |
| Furosemide | 44 | $253 | $6 |
2013: 7 drugs
| Letairis | 45 | $297,372 | $6,608 |
| Tracleer | 26 | $181,584 | $6,984 |
| Adcirca | 25 | $31,343 | $1,254 |
| Revatio | 13 | $25,443 | $1,957 |
| Sildenafil | 17 | $9,128 | $537 |
| Spironolactone | 27 | $457 | $17 |
| Furosemide | 36 | $200 | $6 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1477629178
- Licence
- CA A99234, NY 241178California A99234: Current · expires 2027-03-31
- Trained
- University of Pittsburgh School of Medicine, 2003
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RP1001X (207RP1001X); Internal medicine (207R00000X); Federal specialty code 207RC0200X (207RC0200X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-11-27
- NPI last updated
- 2024-04-17
- NPI record certified
- 2024-04-17
This is when the NPI record was last certified, not a medical board exam.